STAT3 signal transduction through interleukin-22 in oral squamous cell carcinoma

International Journal of Oncology

Volumn 41, Issue 5, 2012, Pages 1577-1586

  Naher, Lutfun ^a   Kiyoshima, Tamotsu ^a   Kobayashi, Ieyoshi ^a   Wada, Hiroko ^a   Nagata, Kengo ^a   Fujiwara, Hiroaki ^a   Ookuma, Yukiko F ^a   Ozeki, Satoru ^b   Nakamura, Seiji ^a   Sakai, Hidetaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

Cell differentiation; IL 22; Squamous cell carcinoma; STAT3

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR; INTERLEUKIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PROTEIN BCL X; SERINE; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; SURVIVIN; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIGENS, NEOPLASM; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKINS; KERATINOCYTES; MOUTH NEOPLASMS; NF-KAPPA B; PROTEIN TRANSPORT; RECEPTORS, INTERLEUKIN; SERPINS; STAT3 TRANSCRIPTION FACTOR;

EID: 84867808604     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1594     Document Type: Article

References (45)

1. Chidzonga MM and Mahomva L: Squamous cell carcinoma of the oral cavity, maxillary antrum and lip in a Zimbabwean population: a descriptive epidemiological study. Oral Oncol 42: 184-189, 2006. (Pubitemid 43106883)
2. Chidzonga MM: Oral malignant neoplasia: a survey of 428 cases in two Zimbabwean hospitals. Oral Oncol 42: 177-183, 2006.
3. Dimery IW and Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95-111, 1993. (Pubitemid 23028714)
4. Schantz SP and Yu GP: Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg 128: 268-274, 2002. (Pubitemid 34218579)
5. Llewellyn CD, Linklater K, Bell J, Johnson NW and Warnakulasuriya KA: Squamous cell carcinoma of the oral cavity in patients aged 45 years and under: a descriptive analysis of 116 cases diagnosed in the South East of England from 1990 to 1997. Oral Oncol 39: 106-114, 2003. (Pubitemid 36050916)
6. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854, 2002. (Pubitemid 35231542)
7. Négrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Pérol D and Lasset C: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 13: 1460-1468, 2002.
8. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411: 380-384, 2001.
9. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX, Nau F, Guillet G, Dagregorio G, Yssel H, et al: A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 150: 407-415, 2007. (Pubitemid 350098734)
10. Wolk K and Sabat R: Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 17: 367-380, 2006. (Pubitemid 44572879)
11. Trifari S, Kaplan CD, Tran EH, Crellin NK and Spits H: Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10: 864-871, 2009.
12. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K and Sabat R: IL-22 increases the innate immunity of tissues. Immunity 21: 241-254, 2004. (Pubitemid 39094053)
13. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ and Renauld JC: Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 277: 33676-33682, 2002.
14. Radaeva S, Sun R, Pan HN, Hong F and Gao B: Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332-1342, 2004. (Pubitemid 38569055)
15. Ziesché E, Bachmann M, Kleinert H, Pfeilschifter J and Mühl H: The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 282: 16006-16015, 2007.
16. Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J and Tian Z: Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14: 6432-6439, 2008.
17. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, Weighardt H and Essler M: IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 177: 8266-8272, 2006. (Pubitemid 44846349)
18. Nagakawa H, Shimozato O, Yu L, Takiguchi Y, Tatsumi K, Kuriyama T and Tagawa M: Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts. Scand J Immunol 60: 449-454, 2004. (Pubitemid 39487511)
19. Matsuo K, Ishibashi Y, Kobayashi I, Ozeki S, Ohishi M, Tange T, Hirata J, Kiyoshima T and Sakai H: New human oral squamous carcinoma cell line and its tumorigenic subline producing granulocyte colony-stimulating factor. Jpn J Cancer Res 85: 1257-1262, 1994.
20. Takahashi K, Kanazawa H, Akiyama Y, Tasaki S, Takahara M, Muto T, Tanzawa H and Sato K: Establishment and characterization of a cell line (SAS) from poorly differentiated human squamous cell carcinoma of the tongue. J Jpn Stomatol Soc 38: 20-28, 1989.
21. Morifuji M, Taniguchi S, Sakai H, Nakabeppu Y and Ohishi M: Differential expression of cytokeratin after orthotopic implantation of newly established human tongue cancer cell lines of defined metastatic ability. Am J Pathol 156: 1317-1326, 2000. (Pubitemid 30660010)
22. Yuan JS, Reed A, Chen F and Stewart CN Jr: Statistical analysis of real-time PCR data. BMC Bioinformatics 7: 85, 2006.
23. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K, Volk HD, Sterry W and Sabat R: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36: 1309-1323, 2006.
24. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC and Morel F: IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174: 3695-3702, 2005. (Pubitemid 40354080)
25. Lee TL, Yeh J, Van Waes C and Chen Z: Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5: 8-19, 2006.
26. Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, Su JL and Hsieh CY: The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway. Oncogene 20: 5799-5809, 2001. (Pubitemid 32937949)
27. Zhong H and Simons JW: Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 259: 523-526, 1999. (Pubitemid 29335566)
28. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y and Yoshizaki K: IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 314: 363-369, 2004. (Pubitemid 38084725)
29. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: 0034, 2002.
30. Kato H and Torigoe T: Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40: 1621-1628, 1977. (Pubitemid 8221737)
31. Duk JM, de Bruijn HW, Groenier KH, Hollema H, ten Hoor KA, et al: Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 39: 186-194, 1990. (Pubitemid 20372410)
32. Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG and Aalders JG: Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 14: 111-118, 1996. (Pubitemid 26020003)
33. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, et al: Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24: 209-218, 2003. (Pubitemid 37500571)
34. Zhong Z, Wen Z and Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994. (Pubitemid 24144493)
35. Schuringa JJ, Schepers H, Vellenga E and Kruijer W: Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett 495: 71-76, 2001. (Pubitemid 32367976)
36. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C and Tannapfel A: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24: 6699-6708, 2005. (Pubitemid 41486800)
37. Hernández-Quintero M, Kuri-Harcuch W, González Robles A and Castro-Muñozledo F: Interleukin-6 promotes human epidermal keratinocyte proliferation and keratin cytoskeleton reorganization in culture. Cell Tissue Res 325: 77-90, 2006.
38. Eichner R, Bonitz P and Sun TT: Classification of epidermal keratins according to their immunoreactivity, isoelectric point, and mode of expression. J Cell Biol 98: 1388-1396, 1984. (Pubitemid 14128923)
39. Fuchs E: Epidermal differentiation: the bare essentials. J Cell Biol 111: 2807-2814, 1990.
40. Porter RM, Leitgeb S, Melton DW, Swensson O, Eady RA and Magin TM: Gene targeting at the mouse cytokeratin 10 locus: severe skin fragility and changes of cytokeratin expression in the epidermis. J Cell Biol 132: 925-936, 1996.
41. Fuchs E and Weber K: Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63: 345-382, 1994.
42. Fuchs E: Keratins and the skin. Annu Rev Cell Dev Biol 11: 123-153, 1995.
43. Suminami Y, Nagashima S, Murakami A, Nawata S, Gondo T, Hirakawa H, Numa F, Silverman GA and Kato H: Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells. Cancer Res 61: 1776-1780, 2001. (Pubitemid 32691982)
44. Hashimoto K, Kiyoshima T, Matsuo K, Ozeki S and Sakai H: Effect of SCCA1 and SCCA2 on the suppression of TNF-alpha-induced cell death by impeding the release of mitochondrial cytochrome c in an oral squamous cell carcinoma cell line. Tumour Biol 26: 165-172, 2005. (Pubitemid 41379742)
45. Ahmed ST and Darnell JE Jr: Serpin B3/B4, activated by STAT3, promote survival of squamous carcinoma cells. Biochem Biophys Res Commun 378: 821-825, 2009.